Clinical-stage biopharmaceutical company founded in 2015, developing first-in-class therapeutic antibodies and innovative combination therapies for cancer and autoimmune diseases
Clinical-stage biopharmaceutical company founded in 2015, developing first-in-class therapeutic antibodies and innovative combination therapies for cancer and autoimmune diseases. Its pipeline is based on proprietary immunology and antibody technology platforms. Lead program XKH002 is a humanized IgG4 monoclonal antibody targeting B7S1/B7-H4, designed to restore anti-tumor immune responses; it has received IND approval in China and the United States.